Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2017 07:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
October 10, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
September 11, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market

SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
September 05, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
August 31, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission

SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
August 29, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Files NDA Resubmission for Vitaros™

SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that it...
August 02, 2017 16:01 ET | Source: Apricus Biosciences

Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Vitaros Drug-Device Human Factor Studies Successfully Completed Vitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current Quarter Conference Call / Webcast Today, August 2, 2017...
July 26, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call

SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
May 11, 2017 16:01 ET | Source: Apricus Biosciences

Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017 Vitaros Drug-Device Human Factor Studies Underway Operations Funded Through the Third Quarter of 2018 Conference Call /...
May 04, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right